These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 25803196)

  • 21. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck M; Smith U
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular actions of incretin-based therapies.
    Ussher JR; Drucker DJ
    Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
    Pratley R; Saeed ZI; Casu A
    Curr Opin Gastroenterol; 2024 Sep; 40(5):404-412. PubMed ID: 38967917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.